7 results about "Plasma lipids" patented technology

Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and / or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.

The invention belongs to the field of neurological disease diagnosis, and provides a plasma lipid marker for diagnosing Alzheimer's disease and application thereof, and the plasma lipid marker is selected from one or more of PA 16: 016: 0, PE O-18: 022: 4, PE P-16: 022: 4, TG 46: 4-FA18: 2, LPC 22: 4, ChE 22: 4, ChE 22: 0, ChE 20: 2, ChE 18: 0, ChE 16: 1 and ChE 20: 1. According to the present invention, the area under the curve (ROC) of the Alzheimer's disease subject diagnosed by the 11 plasma lipid markers is up to 1, and the Alzheimer's disease patient and the healthy subject can be accurately distinguished; detection can be completed through a venous blood collection method, a traditional cerebrospinal fluid collection method with higher trauma is replaced, and low-trauma and low-cost large-range crowd screening of the Alzheimer's disease is facilitated.

The application belongs to the field of neurological disease diagnosis, and provides a plasma lipid marker for diagnosing Alzheimer's disease and an application thereof. The plasma lipid marker is selected from one or more of PA 16:0_16:0, PE O-18:0_22:4, PE P-16:0_22:4, TG 46:4-FA18:2, LPC 22:4, ChE 22:4, ChE 22:0, ChE 20:2, ChE 18:0, ChE 16:1, ChE 20:1. The area under the curve (ROC) of 11 plasma lipid markers for diagnosing Alzheimer's disease is as high as 1, which can accurately distinguish Alzheimer's disease patients from healthy subjects; the detection can be completed by a method of collecting venous blood, instead of a traditional method of collecting cerebrospinal fluid with higher trauma, and is helpful to realize low-trauma, low-cost mass screening of Alzheimer's disease.

The application belongs to the technical field of metabolic analysis, and particularly relates to an evaluation system for screening exercise-related metabolic markers of obese patients and application thereof. The application provides an evaluation system for screening exercise-related metabolic markers of obese patients, which comprises an exercise intervention module, a sample processing module, a data analysis module and a result output module. Different indexes of obese people after exercise are evaluated by using the evaluation system, and it is found that the comprehensive influence on the human body is reflected in the metabolic reconstruction of tissues and intertissue and potential metabolite pathways, and is accompanied by the improvement of plasma lipid spectrum, body composition and physiological function. The evaluation system can provide a new idea for the metabolic mechanism of exercise for improving the comprehensive health condition of the human body.

The present application relates to methods, compounds, and compositions for promoting cell COPII coagulation in a subject, modulating plasma lipids in a subject, or treating or preventing a disease, disorder, or condition associated with or caused by dyslipidemia, chyloparticle retention disease, or a symptom thereof.

The application provides a coronary artery disease early prediction model construction method, system, device and medium. The application synchronously collects clinical covariates and fasting plasma lipidomics data of a subject, relies on a quality control system to ensure that the detection data is accurate and reliable, pre-processes and standardizes lipid characteristics, constructs unified model input variables in combination with clinical indicators, divides training sets and validation sets, screens core lipid characteristics in combination with CAD pathological mechanisms, eliminates redundant variables, and strengthens the relevance of characteristics and coronary artery lesions. A multivariate logistic regression model is constructed using the training set, and the validation set is used for evaluation to ensure the model discrimination performance and generalization ability. The key parameters of the model are solidified and a parameter table is formed, and a standardized CAD risk estimation model is established. In clinical application, only a single blood test combined with basic demographic information can quickly quantify the early disease risk, realize efficient screening and accurate risk stratification, and provide an objective basis for early warning and individualized clinical diagnosis and treatment of coronary artery disease.

The invention discloses application of a plasma lipid marker in an early diagnosis kit for pheochromocytoma of adrenal gland. The plasma lipid marker comprises LPC 18: 1, PC 6: 032: 2, PC 36: 5, TG 8: 08: 035: 1 and SM 35: 1. The ratio of O2 to Cer is 12: 0; o2 / 22: 5 is any one or more; the ratio of the LPC is 18: 1, the ratio of the PC is 6: 032: 2, the ratio of the PC is 36: 5, the ratio of the TG is 8: 08: 035: 1, and the ratio of the SM is 35: 1; the ratio of O2 to Cer is 12: 0; the accuracy of distinguishing a healthy subject from an adrenal pheochromocytoma patient by any one or combination of O2 / 22: 5 reaches 85% or above; therefore, the marker has high diagnosis accuracy on the pheochromocytoma of the adrenal gland and can be used for preparing a kit for early diagnosis of healthy people suffering from the pheochromocytoma of the adrenal gland.